AU747385C - Use of lactoferin in the treatment of allergen induced disorders - Google Patents

Use of lactoferin in the treatment of allergen induced disorders

Info

Publication number
AU747385C
AU747385C AU69647/98A AU6964798A AU747385C AU 747385 C AU747385 C AU 747385C AU 69647/98 A AU69647/98 A AU 69647/98A AU 6964798 A AU6964798 A AU 6964798A AU 747385 C AU747385 C AU 747385C
Authority
AU
Australia
Prior art keywords
lactoferrin
inflammatory
induced
tnf
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU69647/98A
Other languages
English (en)
Other versions
AU747385B2 (en
AU6964798A (en
Inventor
Orla M. Conneely
Marie Cumberbatch
Rebecca J. Dearman
Ian Kimber
Pauline Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix Inc
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Publication of AU6964798A publication Critical patent/AU6964798A/en
Publication of AU747385B2 publication Critical patent/AU747385B2/en
Application granted granted Critical
Publication of AU747385C publication Critical patent/AU747385C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU69647/98A 1997-04-10 1998-04-10 Use of lactoferin in the treatment of allergen induced disorders Ceased AU747385C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4189097P 1997-04-10 1997-04-10
US60/041890 1997-04-10
PCT/US1998/007234 WO1998044940A1 (en) 1997-04-10 1998-04-10 Use of lactoferin in the treatment of allergen induced disorders

Publications (3)

Publication Number Publication Date
AU6964798A AU6964798A (en) 1998-10-30
AU747385B2 AU747385B2 (en) 2002-05-16
AU747385C true AU747385C (en) 2003-01-30

Family

ID=21918897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69647/98A Ceased AU747385C (en) 1997-04-10 1998-04-10 Use of lactoferin in the treatment of allergen induced disorders

Country Status (12)

Country Link
US (1) US20030190303A1 (enExample)
EP (1) EP0979099B1 (enExample)
JP (1) JP2001519815A (enExample)
CN (1) CN1262625A (enExample)
AT (1) ATE297755T1 (enExample)
AU (1) AU747385C (enExample)
CA (1) CA2285960A1 (enExample)
DE (1) DE69830582T2 (enExample)
ES (1) ES2245028T3 (enExample)
IL (1) IL132293A0 (enExample)
NZ (1) NZ500712A (enExample)
WO (1) WO1998044940A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050076A1 (en) * 1997-05-03 1998-11-12 Board Of Regents, The University Of Texas System Methods for preventing and treating the insult-induced metabolic imbalance in humans and other animals
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CN100384472C (zh) * 2000-01-14 2008-04-30 明治乳业株式会社 抗原特异性IgE抗体产生抑制剂
RU2165769C1 (ru) * 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
JP3668241B2 (ja) * 2001-12-28 2005-07-06 株式会社Ｎｒｌファーマ 脂質代謝改善用組成物
JP3806427B2 (ja) * 2002-01-21 2006-08-09 株式会社Ｎｒｌファーマ 新規鎮痛剤
AU2003273182B8 (en) * 2002-05-10 2009-05-07 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
WO2003099207A2 (en) 2002-05-24 2003-12-04 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
NZ566539A (en) 2002-09-06 2010-01-29 Medarex Inc Therapeutic human anti-IL-1R1 monoclonal antibody
DE60335997D1 (de) * 2002-09-16 2011-03-24 Agennix Inc Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
US20040152624A1 (en) * 2002-12-06 2004-08-05 Atul Varadhachary Oral lactoferrin in the treatment of sepsis
US7592306B2 (en) 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8105615B2 (en) * 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
US20090203586A1 (en) * 2004-06-11 2009-08-13 Syngenta Limited Method for ameliorating an inflammatory skin condition
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
WO2006098625A1 (en) 2005-03-15 2006-09-21 Campina Nederland Holding B.V. Dermatologic use of milk proteins
US8178486B2 (en) * 2005-07-21 2012-05-15 Animal Technology Institute Taiwan Method for promoting hair growth
AU2006300009A1 (en) * 2005-10-14 2007-04-19 Auckland Uniservices Limited Use of lactoferrin fragments and hydrolysates
EP1952818A4 (en) * 2005-10-27 2009-10-21 Sunstar Inc OSTEOCLASTICIZATION PREPARATION, ORAL AGGREGATION AND PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST BONE DISEASES WITH LACTOFERRIN-CONTAINING LIPOSOME
EP2560679A4 (en) * 2010-04-23 2013-09-18 Probiotec Ltd TREATMENT OF ECZEMA
CN102370964B (zh) * 2010-08-16 2015-12-09 李兴德 白细胞介素受体拮抗蛋白在制备皮肤外用制剂中的应用
IT201800002457A1 (it) * 2018-02-07 2019-08-07 Neilos S R L Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
PL4072322T3 (pl) * 2019-12-11 2025-05-19 N.V. Nutricia Kompozycja do żywienia do poprawy sprawności układu odpornościowego
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
CN115737787B (zh) * 2022-12-15 2024-04-19 四川大学 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707476B2 (en) * 1996-05-31 1999-07-08 Baylor College Of Medicine Lactoferrin variants and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641696B2 (fr) * 1986-04-11 1991-03-08 Sederma Sa Utilisation d'un melange renfermant de la lactoferrine dans des preparations cosmetiques anti-radicaux libres
FR2596986B1 (fr) * 1986-04-11 1988-09-23 Sederma Sa Utilisation de la lactoferrine dans des preparations cosmetiques, antiradicaux libres
FR2685202B1 (fr) * 1991-12-24 1995-03-24 Sederma Sa Nouvelle methode de traitement pharmaceutique et cosmetique pour la regulation de la seborrhee, de l'acne et de la flore cutanee.
JP3184923B2 (ja) * 1992-01-08 2001-07-09 ビオ セレ ラボラトワール エス ア 抗リウマチ剤
JPH05279266A (ja) * 1992-04-02 1993-10-26 Imuno Japan:Kk 歯周病の治療・予防用医薬組成物
JP3163171B2 (ja) * 1992-07-15 2001-05-08 森永乳業株式会社 ＩｇＡ産生促進剤
JP3746081B2 (ja) * 1994-02-24 2006-02-15 森永乳業株式会社 動物皮膚病治療剤
JPH0859450A (ja) * 1994-08-18 1996-03-05 Kose Corp 皮膚外用剤
JP2832517B2 (ja) * 1994-12-09 1998-12-09 雪印乳業株式会社 大腸菌付着阻止剤
JP3911642B2 (ja) * 1995-06-06 2007-05-09 株式会社加美乃素本舗 皮膚外用剤
JP3888707B2 (ja) * 1996-01-22 2007-03-07 森永乳業株式会社 血管新生病治療剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707476B2 (en) * 1996-05-31 1999-07-08 Baylor College Of Medicine Lactoferrin variants and uses thereof

Also Published As

Publication number Publication date
CN1262625A (zh) 2000-08-09
AU747385B2 (en) 2002-05-16
EP0979099A1 (en) 2000-02-16
IL132293A0 (en) 2001-03-19
WO1998044940A1 (en) 1998-10-15
DE69830582T2 (de) 2006-05-04
ATE297755T1 (de) 2005-07-15
ES2245028T3 (es) 2005-12-16
NZ500712A (en) 2002-10-25
CA2285960A1 (en) 1998-10-15
JP2001519815A (ja) 2001-10-23
DE69830582D1 (de) 2005-07-21
US20030190303A1 (en) 2003-10-09
EP0979099B1 (en) 2005-06-15
AU6964798A (en) 1998-10-30

Similar Documents

Publication Publication Date Title
AU747385C (en) Use of lactoferin in the treatment of allergen induced disorders
Camras et al. Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2α
US20210277072A1 (en) Plant-derived elastin binding protein ligands and methods of using the same
JP3122139B2 (ja) 後期段階炎症反応の治療用組成物
US8057802B2 (en) Treatment methods for fibrosis related disorders
DE69228700T2 (de) Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände
JPS62501002A (ja) 高い眼圧の防止法、緑内障の処置及び高眼圧の処置
JPH07304649A (ja) 化粧品組成物においてサブスタンスｐアンタゴニストを使用する使用方法およびその組成物
US11298353B2 (en) Anti-inflammatory composition
EP1037653B1 (en) Compositions and methods for regulating phagocytosis and icam-1 expression
US7666842B2 (en) Elastin peptide analogs and uses thereof
US20020025316A1 (en) Pharmaceutical composition containing inhibitors of interferon-gamma
EP0620737B1 (en) Use of LACTOFERRIN iN the manufacture of a medicament for treating RHEUMATISM
Dati et al. Beneficial effects of rh-CLU on disease severity in different animal models of peripheral neuropathies
JP2008501772A (ja) 炎症性皮膚状態を寛解するための方法
EA006881B1 (ru) ПРИМЕНЕНИЕ АКТИВАТОРОВ gp130 ПРИ ДИАБЕТИЧЕСКОЙ НЕВРОПАТИИ
MXPA99009240A (en) Use of lactoferin in the treatment of allergen induced disorders
Zwadlo-Klarwasser et al. The effects of the glucocorticoids prednisolone, deflazacort and beclomethasone-dipropionate on the RM 3/1 macrophage in human peripheral blood
Sorbera et al. Adalimumab
AU2022346513B2 (en) Gel composition for prevention or treatment of atopic dermatitis
KR20060120401A (ko) 알레르기 질환의 치료를 위한 약학적 조성물, 그의 용도 및알레르기 질환의 치료방법
JP2023070539A (ja) オートファジー活性化剤
KR20220164450A (ko) Agkistrodon piscivorus piscivorus 또는 Naja melanoleuca로부터 유래된 신규한 펩타이드, 및 이를 포함하는 베체트병 또는 류마티스 관절염의 치료용 조성물
Saab et al. Jack Jeskey, Lauren Fill, Madiha Huq, Sandeep Sarkaria
US5385731A (en) Method of treating hyperlipidemia with granulocyte colony stimulating factor

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20020628

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20020725